ERBB2 and pachyonychia congenita: HER2 overexpression has been described in 10% of cases, but historical data have shown a difference in the frequency of HER2 positivity depending on disease stage and hormone resistance, with a stronger prevalence among metastatic, castration-resistant patients compared with localized, hormone-dependent PC patients (78% vs. 25%) [119].